Author Affiliations: Dr DeAngelis is Editor in Chief and Dr Fontanarosa (firstname.lastname@example.org) is Executive Deputy Editor, JAMA.
The benefits and risks associated with pharmaceutical agents and medical devices have received increasing attention from the medical community, the public, and government agencies. Serious concerns about US Food and Drug Administration (FDA) capabilities and oversight for ensuring accurate determination of safety and efficacy, appropriate mechanisms and decisions regarding drug and device approval, and effective postmarketing surveillance have prompted investigations by the Institute of Medicine1 and by an FDA blue ribbon commission.2 Major legislation3 has been enacted to improve the agency's ability to fulfill the daunting responsibility of ensuring that pharmaceutical products and medical devices approved for marketing are safe.4
DeAngelis CD, Fontanarosa PB. Prescription Drugs, Products Liability, and Preemption of Tort Litigation. JAMA. 2008;300(16):1939–1941. doi:10.1001/jama.2008.513
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: